Summary:
28-day study for women experiencing acute symptoms of urinary tract infection (UTI). This is a phase 3, randomized, double-blind study of the efficacy, tolerability, and safety of oral sulopenum etzadroxil/probenecid versus oral coprofloxacin for treatment of uncompicated urinary tract infections in adult women.
Qualified Participants Must:
• Be female
• be age 18+
• have 2 or more symptoms: urinary frequency, urinary urgency, pain or burning upon urination, suprapubic pain
• onset of symptoms within the past 24-72 hours
Qualified Participants May Receive:
Urinalysis at screening; treatment of confirmed UTI with investigational product or ciprofloxacin; compensation for time/travel